特种非专利的全球市场规模、份额和成长分析：按类型和应用分类 - 产业预测（2024-2031）

Global Specialty Generics Market Size, Share, Growth Analysis, By Type(Oral, injectable), By Application(Oncology, neurology) - Industry Forecast 2024-2031

出版日期: 2024年03月06日 | 出版商:

SkyQuest | 英文 182 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球特种非专利市场规模将为733.8亿美元，从2023年的801.3亿美元扩大到2031年的1620.2亿美元，并将从2031年的1620.2亿美元增长到2031年的1620.2亿美元。）预计成长复合年增长率为 9.2%。

特种非专利，或旨在治疗特定疾病的专利到期药物，包含在全球特种非专利市场。这一市场成长的推动因素包括降低医疗成本、专利到期以及对名牌药物的负担得起的替代品的需求不断增长。该市场的特点是配方复杂、治疗领域广泛和监管障碍。另一个优点是可以以合理的价格提供治疗药物。随着製药公司专注于开发、生产和合规性，策略性收购和联盟变得更加重要。市场的未来将由创新和可及的治疗方法的开拓、医疗保健政策的变化以及定价和给药技术的压力决定。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 其他欧洲国家
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲

竞争形势

前5名企业对比
主要企业市场定位（2021年）
主要市场参与者所采取的策略
关键成功策略
近期市集活动
主要企业市场占有率（2021年）

主要企业简介

Teva Pharmaceutical Industries Ltd-Israel
Mylan NV-USA
Sandoz International GmbH（a division of Novartis）-Switzerland
Sun Pharmaceutical Industries Ltd-India
Lupin Limited-India
Dr. Reddy's Laboratories Ltd-India
Apotex Inc.-Canada
Endo International plc-Ireland
Aspen Pharmacare Holdings Limited-South Africa
Mayne Pharma Group Limited-Australia
Perrigo Company plc-Ireland
Glenmark Pharmaceuticals Ltd-India
Amneal Pharmaceuticals LLC-USA
Hikma Pharmaceuticals PLC-Jordan
Fresenius Kabi AG-Germany
Aurobindo Pharma Limited-India
Zydus Cadila-India
Cipla Limited-India
Torrent Pharmaceuticals Ltd-India
Alvogen-USA

简介目录

Product Code: SQMIG55E2036

Global Specialty Generics Market size was valued at USD 73.38 billion in 2022 and is poised to grow from USD 80.13 billion in 2023 to USD 162.02 billion by 2031, growing at a CAGR of 9.2% during the forecast period (2024-2031).

Specialty generics, or off-patent pharmaceuticals designed to treat certain ailments, are included in the Global Specialty Generics Market. Its expansion is driven by efforts to reduce healthcare costs, patent expirations, and the growing need for affordable substitutes for name-brand medications. This market is distinguished by complicated formulations, a wide range of therapeutic areas, and regulatory obstacles. It also benefits from the possibility of providing reasonably priced remedies. Strategic acquisitions and alliances become even more important as pharmaceutical businesses concentrate on development, production, and compliance. The market's future is shaped by the development of innovative and accessible therapies, changing healthcare policy, and pressures on prices and drug delivery technology.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Specialty Generics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Specialty Generics Market Segmental Analysis

Type, application, and geography are the three main ways to divide up the worldwide specialty generics market. Oral, injectable, topical, and other forms are available to accommodate different preferences for administration. Applications include illnesses of the central nervous system, cardiology, and cancer. North America, Europe, Asia-Pacific, and the rest of the globe make up the market's geographical boundaries.

Drivers of the Global Specialty Generics Market

Specialty generics are a popular choice for consumers and healthcare professionals looking for cost-effective treatment options because they are frequently less expensive than name-brand specialty medications. The need for reasonably priced drugs, particularly for complicated and long-term ailments, fuels the expansion of the specialty generics industry as healthcare expenses keep rising.

Restraints in the Global Specialty Generics Market

Complex production procedures, delivery systems, and formulations are frequently used in specialty generics. These drugs can be difficult to develop and produce, requiring specific knowledge and facilities. Due to its complexity, fewer manufacturers may be able to produce these generics, which could result in a lack of supply.

Market Trends of the Global Specialty Generics Market

The intricacy of specialty generics is what sets them apart; they frequently have complex formulations, delivery systems, or manufacturing procedures. The increasing need for complicated generics, which are more difficult to create and produce than conventional generic medications, was one significant trend. When compared to their name-brand equivalents, these sophisticated generics can save a considerable amount of money, but they frequently demand a greater degree of experience and effort. Biosimilars, transdermal patches, inhalation devices, and extended-release formulations are a few examples. Specialty generics, which addressed a range of therapeutic areas like oncology, disorders of the central nervous system, and autoimmune diseases, were becoming more and more prevalent in the market.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Specialty Generics Market by Type

Market Overview
Oral
injectable
topical
and others

Global Specialty Generics Market by Application

Market Overview
Oncology
neurology
autoimmune diseases
and others

Global Specialty Generics Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Teva Pharmaceutical Industries Ltd - Israel
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. - USA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sandoz International GmbH (a division of Novartis) - Switzerland
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd - India
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Limited - India
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories Ltd - India
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Apotex Inc. - Canada
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Endo International plc - Ireland
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aspen Pharmacare Holdings Limited - South Africa
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mayne Pharma Group Limited - Australia
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Perrigo Company plc - Ireland
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Glenmark Pharmaceuticals Ltd - India
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amneal Pharmaceuticals LLC - USA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hikma Pharmaceuticals PLC - Jordan
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius Kabi AG - Germany
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurobindo Pharma Limited - India
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zydus Cadila - India
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Limited - India
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Torrent Pharmaceuticals Ltd - India
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alvogen - USA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments